Etanercept and demyelinating disease in a patient with psoriasis - 09/08/11
Reprint requests: Richard D. Granstein, MD, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021.New York, New York
Abstract |
The tumor necrosis factor-⍺ antagonist (TNF-⍺) etanercept has been approved for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. Earlier reports on the use of etanercept or infliximab in patients with rheumatoid arthritis, psoriatic arthritis, or juvenile rheumatoid arthritis suggested an increased risk of demyelinating disease. It is imperative that dermatologists have a keen awareness of this possible adverse event given the increased use of this class of drugs. We report a case of demyelinating disease occurring in a patient treated for psoriasis. The relation of TNF-⍺ antagonist therapy to demyelinating disease/multiple sclerosis is explored. It is recommended that patients be diligently screened before starting TNF-⍺ antagonist therapy and that vigilance for symptoms of demyelinating disease/multiple sclerosis be included in follow-up examinations during treatment with these drugs.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None identified. Presented at the 63rd Annual Meeting of the American Academy of Dermatology, February 18-22, 2005, New Orleans, LA. |
Vol 54 - N° 1
P. 160-164 - janvier 2006 Retour au numéro
Article précédent
- Nephrogenic fibrosing dermopathy: A series in a non-Western population
- Saumya Panda, Debabrata Bandyopadhyay, Avijit Tarafder
- Woolly hair in 4 members of a Chinese family
- Catherine Chen, Philip E. LeBoit, Vera H. Price
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?